Embracing the Contact Sport of Innovation
AsianScientist (Apr. 25, 2019) – No two people are the same, yet many of our treatments for serious diseases fail to see the patient as an individual. Because of this, many therapies work sub-optimally, or patients experience side effects. By delivering the right amount of drugs to the right location at the right time, we…
This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.
Key takeaways
25, 2019) – No two people are the same, yet many of our treatments for serious diseases fail to see the patient as an individual.
Because of this, many therapies work sub-optimally, or patients experience side effects.
By delivering the right amount of drugs to the right location at the right time, we…
Get featured
Want to get featured in MarketScale Sciences?
Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.
AsianScientist (Apr. 25, 2019) – No two people are the same, yet many of our treatments for serious diseases fail to see the patient as an individual. Because of this, many therapies work sub-optimally, or patients experience side effects. By delivering the right amount of drugs to the right location at the right time, we can enhance treatment outcomes and improve the lives of patients, and I believe that we can achieve these goals with nanotechnology.
Your experts belong here
Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.
Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.
About the author
